TECOS: A Cardiovascular Outcomes Study for Type 2 Diabetes

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-006719-20

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To compare the impact of including sitagliptin as part of usual care vs. usual care without sitagliptin on CV outcomes as measured by the time to first event in the primary CV composite endpoint of CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization.


Critère d'inclusion

  • Type 2 Diabetes Mellitus (T2DM)